Frontline Lenalidomide for AL Amyloidosis Involving Myocardium

Status Completed

Clinical Trial Summary

This phase II clinical trial aimed at influencing the improvement of major organ functions, especially the objective response rate, in Amyloid light-chain amyloidosis involving myocardium.

Clinical Trial Description

This study was designed according to the 18F-florbetaben positron emission tomography imaging, which successfully demonstrated a significant reduction in the amount of amyloid in the heart when administered by merging thalidomide and dexamethasone in patients involving myocardium, and reported that this reaction leads to an improvement in cardiac function. Amyloid light-chain amyloidosis patients at age 19 or older with refractory or relapsed who participants should have never been exposed to lenalidomide within 5 years. Planned initial dosage of the current regimen are as follow; - Lenalidomide : D1~D21 daily oral administration, starting dose 15mg, with an increase of 5mg every cycle, if tolerated, up to 25mg. - Dexamethasone : D1~D4 daily oral administration or intravenous injection, 40mg(or 20mg for age for age ≥ 65 years old) Patients will be treated every 4 weeks as one cycle, and up to 12 cycles of treatment will be conducted. The investigator is working on a total of 30 patients, the primary endpoint of this study is objective response rate and secondary endpoints are cardiac/renal/hepatic function, 18F-florbetaben positron emission tomography imaging parameter, overall survival period, progression-free survival period, toxicity profile. ;

Study Design

Related Conditions & MeSH terms

Amyloidosis
Amyloidosis Cardiac
Immunoglobulin Light-chain Amyloidosis

Clinical Trial Details

NCT number	NCT04298372
Study type	Interventional
Source	Seoul National University Hospital
Contact
Status	Completed
Phase	Phase 3
Start date	February 20, 2019
Completion date	November 25, 2021

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04985734` - Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy	N/A
Recruiting	`NCT05489549` - Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
Enrolling by invitation	`NCT05718401` - The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics
Recruiting	`NCT05167799` - Cardiac Contractility Modulation Therapy in Amyloid Cardiomyopathy Patients With Heart Failure
Completed	`NCT03996382` - Prevalence of Wild Type Transthyretin Cardiac Amyloidosis in Patients Operated for Idiopathic Carpal Tunnel Syndrome	N/A
Recruiting	`NCT06066632` - Analysis of Calcium Score of Severe Aortic Stenosis in Patients With and Without Cardiac Amyloidosis (CAUSATIVE Study)
Recruiting	`NCT05379101` - Intracardiac Flow Assessment in Cardiac Amyloidosis
Recruiting	`NCT06186167` - Amyloidosis Incidence in High-Risk Cardiac Device Patients
Recruiting	`NCT06251778` - NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis
Recruiting	`NCT03984877` - Impact of Amyloidosis on TAVI Patients
Not yet recruiting	`NCT05938218` - Virtual Reality Assisted Patient Empowerment: Diagnose ATTR-Amyloidosis And Start Treatment	N/A
Recruiting	`NCT04667494` - Ultrasound Therapy In Cardiac Amyloidosis	Phase 4
Active, not recruiting	`NCT04061213` - ATTR Amyloidosis in Elderly Patients With Aortic Stenosis
Recruiting	`NCT04587648` - Cardiac Amyloidosis in HFpEF